CD274 and melanoma: Here we investigated the clinical and translational aspects of the “priming” combination of hypomethylating and DNA-damaging agents in an early phase II study of azacitidine and carboplatin priming for anti-PDL1 immunotherapy (avelumab) in patients with advanced melanoma who were resistant to ICB (PRIME002: ACTRN12618000053224).